Your browser doesn't support javascript.
loading
Pediatric and adolescent HIV viral load coverage and suppression rates in the context of the COVID-19 pandemic in 12 PEPFAR-supported sub-Saharan African countries in 2019 and 2020.
Carpenter, Deborah; Hast, Marisa; Buono, Nicole; Hrapcak, Susan; Sato, Kimi; Mrina, Rosemary; Cox, Mackenzie Hurlston; Agaba, Patricia Aladi; Vrazo, Alexandra C; Wolf, Hilary; Rivadeneira, Emilia D; Shang, Judith D; Mayer, Magdalene Mange; Prao, Aka Herve; Longuma, Henri Onema; Kabwe, Constantin; Lwana, Patricia Nyembo; Tilahun, Tsegaye; Ts'oeu, Mamorapeli; Mutisya, Immaculate; Omoto, Lennah Nyabiage; Cowan, Jessica Greenberg; Deus, Maria Ines Jorge Tomo de; Fagbamigbe, Omodele Johnson; Ene, Uzoma; Ikpeazu, Akudo; Ndlovu, Mduduzi B; Matiko, Eva; Schaad, Nicolas; Bisimba, Jema; Lema, Elizabeth; Musokotwane, Kebby; Maphosa, Talent; Buthelezi, Buyile; Olarinoye, Adegbenga; Lawal, Ismail; Mukungunugwa, Solomon; Mwambona, Janet Tulibonywa; Wondimu, Teferi; Kathure, Immaculate Anne; Igboelina, Onyeka Donald; Nzima, Valery Nxima; Bissai, Rosine Grace; Lenka, Matjeko; Shasha, Willibrord; Olivier, N'guetta-Kan; Matsinhe, Mѐrcia; Wate, Argentina; Godfrey, Lingenda; Alexander, Heather.
Afiliación
  • Carpenter D; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Hast M; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Buono N; United States Agency for International Development, Washington, District of Columbia, United States of America.
  • Hrapcak S; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Sato K; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Mrina R; Walter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.
  • Cox MH; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
  • Agaba PA; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Vrazo AC; Walter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.
  • Wolf H; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, United States of America.
  • Rivadeneira ED; United States Agency for International Development, Washington, District of Columbia, United States of America.
  • Shang JD; US Department of State, Office of the United States Global AIDS Coordinator, Washington, District of Columbia, United States of America.
  • Mayer MM; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Prao AH; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon.
  • Longuma HO; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon.
  • Kabwe C; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire.
  • Lwana PN; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo.
  • Tilahun T; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo.
  • Ts'oeu M; Ministry of Health, National AIDS Control Committee, Kinshasa, Democratic Republic of Congo.
  • Mutisya I; United States Agency for International Development, Addis Ababa, Ethiopia.
  • Omoto LN; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maseru, Lesotho.
  • Cowan JG; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.
  • Deus MIJT; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.
  • Fagbamigbe OJ; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique.
  • Ene U; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique.
  • Ikpeazu A; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria.
  • Ndlovu MB; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria.
  • Matiko E; Federal Ministry of Health, Abuja, Nigeria.
  • Schaad N; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.
  • Bisimba J; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.
  • Lema E; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.
  • Musokotwane K; United States Agency for International Development, Dar es Salaam, Tanzania.
  • Maphosa T; United States Agency for International Development, Dar es Salaam, Tanzania.
  • Buthelezi B; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia.
  • Olarinoye A; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe.
  • Lawal I; United States Agency for International Development, Pretoria, South Africa.
  • Mukungunugwa S; HJF Medical Research International, Abuja, Nigeria.
  • Mwambona JT; US Army Medical Research Directorate-Africa/ Walter Reed Army Institute of Research, Abuja, Nigeria.
  • Wondimu T; United States Agency for International Development, Harare, Zimbabwe.
  • Kathure IA; Walter Reed Army Institute of Research (WRAIR), Dar es Salaam, Tanzania.
  • Igboelina OD; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Addis Ababa, Ethiopia.
  • Nzima VN; United States Agency for International Development, Nairobi, Kenya.
  • Bissai RG; United States Agency for International Development, Abuja, Nigeria.
  • Lenka M; United States Agency for International Development, Yaounde, Cameroon.
  • Shasha W; United States Agency for International Development, Yaounde, Cameroon.
  • Olivier NK; United States Agency for International Development, Maseru, Lesotho.
  • Matsinhe M; United States Agency for International Development, Abidjan, Côte d'Ivoire.
  • Wate A; United States Agency for International Development, Abidjan, Côte d'Ivoire.
  • Godfrey L; United States Agency for International Development, Maputo, Mozambique.
  • Alexander H; United States Agency for International Development, Maputo, Mozambique.
PLOS Glob Public Health ; 4(8): e0003513, 2024.
Article en En | MEDLINE | ID: mdl-39088480
ABSTRACT
The early period of the COVID-19 pandemic limited access to HIV services for children and adolescents living with HIV (C/ALHIV). To determine progress in providing care and treatment services, we describe viral load coverage (VLC) and suppression (VLS) (<1000 copies/ mL) rates during the COVID-19 pandemic in 12 United States President's Emergency Plan for AIDS Relief (PEPFAR)-supported countries. Data for children (0-9 years) and adolescents (10-19 years) on VLC and VLS were analyzed for 12 sub-Saharan African (SSA) countries between 2019 (pre-COVID-19) and 2020 (during COVID-19). We report the number of viral load (VL) tests, and percent change in VLC and VLS for patients on ART. For 12 countries, 181,192 children had a VL test during the pre-COVID-19 period compared with 177,683 December 2020 during COVID-19. VLC decreased from 68.8% to 68.3% overall. However, 9 countries experienced an increase ranging from a 0.7%-point increase for Tanzania and Zimbabwe to a 15.3%-point increase for Nigeria. VLS increased for all countries from 71.2% to 77.7%. For adolescents the number with a VL test increased from 377,342 to 402,792. VLC decreased from 77.4% to 77.1%. However, 7 countries experienced an increase ranging from 1.8% for Mozambique to 13.8% for Cameroon. VLS increased for all countries from 76.8% to 83.8%. This analysis shows variation in HIV VLC across 12 SSA countries. VLS consistently improved across all countries demonstrating resilience of countries during 2020. Countries should continue to improve clinical outcomes from C/ALHIV despite service disruptions that may occur during pandemic response.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: PLOS Glob Public Health / PLOS global public health Año: 2024 Tipo del documento: Article País de afiliación: Georgia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: PLOS Glob Public Health / PLOS global public health Año: 2024 Tipo del documento: Article País de afiliación: Georgia
...